©Jean Marie Heidinger/Inserm
Space is an extraordinary laboratory for medicine and medical research on Earth. The loss of muscle mass and bone density, and the accelerated ageing of the arteries or disruption of the internal body clock observed in astronauts affected by zero gravity have led to improved knowledge of the human body. There has been a human presence in space almost continuously for over 40 years, and the main concern of the space agencies has always been to ensure astronauts’ health by taking appropriate measures. But in recent years, there have been instruments that allow comprehensive medical monitoring of astronauts, opening the opportunity for basic studies in physiology and medicine, conducted by Inserm and CNES. Moreover, these instruments may also find applications in medical research and public health.
This agreement, signed in the presence of the President of France by Yves Lévy, Chairman and Chief Executive Officer of Inserm and Jean-Yves Le Gall, President of CNES, provides for collaboration in the area of health in order to gain a better understanding of:
Its aim is to develop methods, tools and services based on, among other things, space technologies in the area of health, particularly:
It will also give rise to a large number of experiments during the period spent by Thomas Pesquet on board the international space station. Access to simulation experiments conducted on earth will also be possible, as well as the opportunity to conduct research projects during parabolic flights or in recoverable capsules.
“Thomas Pesquet’s space mission will make it possible to write a new chapter in French excellence in the area of manned flight. With this framework agreement signed with Inserm, medical research will benefit from all the advances enabled by studying the human being in space, and major advantages both for applications and for routine health matters,” stated Jean-Yves Le Gall, President of CNES.
La création d'Accélérateurs de Recherche Technologique est une priorité du plan d'orientation stratégique de l'Inserm. Ce 12 octobre 2017, l'Inserm inaugure son deuxième ART consacré à la "Bioimpression 3D" à Bordeaux. Il s'agit de la seule unité technologique utilisant les trois principales ...
To become the most advanced and competitive genomics research and healthcare system in the world: such was the ambition declared by Inserm, and its partners Aviesan and Genomics England Ltd, during the UK-France Summit on January 18, 2018. An agreement was signed ...